Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside

Dejan Radovanovic; Pierachille Santus; Francesco Blasi; Marco Mantero

doi:10.4081/mrm.2017.244

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside

Authors

Dejan Radovanovic Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Pulmonary Unit, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan
Pierachille Santus Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Pulmonary Unit, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan
Francesco Blasi Department of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan
Marco Mantero Department of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan

DOI: https://doi.org/10.4081/mrm.2017.244

Keywords:

Erratum

Abstract

After publication of the Review article it was brought to our attention that the sentence at the bottom of the section entitled Tiotropium bromide must be corrected as follows: “Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat®....